In contrast, TNS4 exhibits tumor-suppressor–like functions in breast and prostate cancers, where its downregulation promotes tumor growth and angiogenesis via the c-Cbl/β-catenin/VEGFA axis or disrupts normal growth-regulating pathways. Here, VEGFA is linked to prostate carcinoma.